Edwards Lifesciences Corp (NYSE:EW) Receives $239.42 Consensus PT from Analysts

Edwards Lifesciences Corp (NYSE:EW) has been given a consensus rating of “Buy” by the twenty-one analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $239.42.

EW has been the topic of a number of research analyst reports. Raymond James raised their target price on Edwards Lifesciences from $255.00 to $263.00 and gave the company an “outperform” rating in a report on Friday, December 6th. Wells Fargo & Co raised their target price on Edwards Lifesciences from $262.00 to $270.00 and gave the company an “outperform” rating in a report on Friday, December 6th. ValuEngine lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Morgan Stanley raised their target price on Edwards Lifesciences from $248.00 to $270.00 and gave the company an “overweight” rating in a report on Friday, December 6th. Finally, Deutsche Bank initiated coverage on Edwards Lifesciences in a report on Friday, January 3rd. They issued a “hold” rating and a $164.00 target price on the stock.

EW opened at $228.92 on Friday. The firm has a market capitalization of $48.06 billion, a P/E ratio of 62.72, a price-to-earnings-growth ratio of 2.53 and a beta of 0.77. The stock’s 50 day moving average price is $234.32 and its two-hundred day moving average price is $225.87. The company has a quick ratio of 2.74, a current ratio of 3.53 and a debt-to-equity ratio of 0.17. Edwards Lifesciences has a 12-month low of $163.08 and a 12-month high of $247.64.

In other news, VP Catherine M. Szyman sold 2,500 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $242.14, for a total transaction of $605,350.00. Following the sale, the vice president now owns 19,605 shares of the company’s stock, valued at approximately $4,747,154.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Huimin Wang sold 4,650 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $234.83, for a total value of $1,091,959.50. Following the sale, the vice president now directly owns 36,898 shares in the company, valued at approximately $8,664,757.34. The disclosure for this sale can be found here. Insiders have sold a total of 164,241 shares of company stock worth $38,597,230 in the last three months. 1.63% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Manchester Financial Inc. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $26,000. Savior LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $27,000. Quest Capital Management Inc. ADV acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $28,000. Usca Ria LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $34,000. Finally, Venturi Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $50,000. 80.62% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: What is quantitative easing?

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.